De Facto

Public Relations

Back to company list

De Facto Communications, part of Open Health and Chime's international network, is the international consultancy of choice for the best strategic life science and healthcare communications. De Facto has been a leader in its field for over 20-years and its reputation for informed, honest advice, backed by effective service delivery is second to none.

Its experienced teams have constructed and implemented marketing, design, digital, financial and PR communications campaigns through out Europe, the US, the Middle East and Asia - utilising Chime Communications Group's international network. The specialist offering includes website enhancement, brochure, logo and strap line design, SEO, key messaging and positioning refinement, investor relations, including trade sales and listings (with bespoke teams drawn from Pelham Bell Pottinger and De Facto Communications), and corporate, financial, B2B and B2C media communications.

Recent activities include:

• International media launch of VisualSonics (subsidiary of Sonosite)'s VEVO LASR photoacoustics imaging technology
• Raised the profile of The Almac Group and a strong focus on the structured integration of its pharma services, clinical services, clinical technology, diagnostics, sciences and discovery business units and its US expansion programmes
• Raised the profile of Recipharm as a top ten international contract development and manufacturing organisation, specifically highlighting its expertise in both pharmaceutical development and biologics, and generating strong market awareness for the launch of RecipharmCobra Biologics as a new brand created from Recipharm's strategic acquisition of Cobra Biomanufacturing
• Raised InterSystems profile in e-health across Europe, which helped the company to win a landmark deal to be the preferred supplier of Electronic Patient Records to Health Boards in Scotland – the deal could potentially rise to over £100 million
• Secured European wide exposure for Aloka's research collaborations with leading clinicians and key opinion leaders and the ground breaking ramifications of its ultrasound technology
• Developed marketing collateral to launch BNF Knowledge for the British National Formulary

   

 Back to company list